Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST
30 Outubro 2023 - 6:30PM
Business Wire
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome
therapeutics company, today announced that it will release third
quarter 2023 financial results on Thursday, November 2, 2023.
Management will host a conference call with investors to discuss
the results and corporate updates at 8:00 a.m. ET.
The conference call may be accessed by calling 1-866-777-2509
(international callers dial 1-412-317-5413). Participants may
pre-register for the conference call at
https://dpregister.com/sreg/10184132/faf729b9c0
To join the live webcast, please visit the “Investors and News”
section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website
beginning approximately two hours after the event and will be
archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage
company developing novel microbiome therapeutics for serious
diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval
in April 2023 as the first orally administered microbiome
therapeutic to prevent recurrence of C. difficile infection (CDI)
in adults following antibacterial treatment for recurrent CDI and
is being commercialized in collaboration with Nestlé Health
Science. Seres is evaluating SER-155 in a Phase 1b study in
patients receiving allogeneic hematopoietic stem cell
transplantation. The Company is also conducting research to inform
further development of microbiome therapeutics for ulcerative
colitis. For more information, please visit
www.serestherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231030359303/en/
Seres IR and PR Contact: Kevin Mannix
kmannix@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Seres Therapeutics (NASDAQ:MCRB)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024